REG - Solvonis Therapeutic - Total Voting Rights

Solvonis TherapeuticsAnnouncement

30/05/2025 17:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250530:nRSd8050Ka&default-theme=true

RNS Number : 8050K  Solvonis Therapeutics PLC  30 May 2025

30 May 2025
Solvonis Therapeutics plc

("Solvonis" or the "Company")

Total Voting Rights

 

Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical
company focused on developing innovative medicines for the treatment of
addiction and mental health disorders, confirms that the Company's issued
share capital as at the date of this announcement comprises 5,908,770,690
Ordinary Shares with one voting right each. The Company does not hold any
Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares
and voting rights in the Company is 5,908,770,690.

The above figure may be used by shareholders in the Company as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the share capital
of the Company.

Enquiries:

 Solvonis Therapeutics plc                                      anthony@solvonis.com
 Anthony Tennyson, CEO & Executive Director

 Allenby Capital Limited (Financial Adviser and Joint Broker)   +44 (0) 20 3328 5656
 Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)

 Guy McDougall (Sales & Corporate Broking)

 Singer Capital Markets (Joint Broker)                          +44(0) 20 7496 3000
 Phil Davies

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVREANSEDDXSEEA